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BACKGROUND/PURPOSE: Aggregatibacter (Actinobacillus) actinomycetemcomitans, part of the normal 
flora of the mouth, is frequently found in human periodontal cultures and is an important pathogen 
causing various invasive infections, particularly infective endocarditis. In this study, we describe the clini-
cal course and outcome of patients with A. actinomycetemcomitans infection.
METHODS: All patients suffering invasive A. actinomycetemcomitans infections at the National Taiwan 
University Hospital from January 1985 to December 2004 were included in this study. Relevant data 
regarding clinical presentation, antimicrobial treatment and outcome of these patients were analyzed.
RESULTS: During the study period, there were 11 patients with invasive A. actinomycetemcomitans infec-
tions, including eight patients with infective endocarditis, one with osteonecrosis and two with pneumo-
nia and chest wall lesions. Among the patients with infective endocarditis, four had prosthetic valve 
replacement, four suffered from rheumatic heart disease and one had undergone surgical repair of ven-
tricular septal defect. Lesions in the oral cavity were the probable portals of entry of the microorganism, 
and included carious teeth, periodontitis or radiotherapy of the ear–nose–throat field, and were noted in 
nine patients. Transthoracic echocardiography and/or transesophageal echocardiography were performed 
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Introduction
Aggregatibacter (Actinobacillus) actinomycetemcomitans is a 
slow-growing, capnophilic Gram-negative coccobacillus, 
first described by Klinger in 1912.1 The species was so 
named for its close association with the ray fungus 
Actinomyces israelii.1 The first human case was described by 
Thjotta and Sydnes in 1951.2 Endocarditis caused by this 
organism was first reported by Vallee and Gaillard in 1953.3 
In 1962 King and Tatum reported 32 well-documented 
A. actinomycetemcomitans infections, and 23 of these patients 
had endocarditis.4 In 1959, Heinrich and Pulverer demon-
strated that A. actinomycetemcomitans was part of the normal 
mouth flora.5 It is commonly found in human periodontal 
cultures and its pathogenic role in periodontitis is well estab-
lished.6 A. actinomycetemcomitans is a member of the HACEK 
group of bacteria together with Haemophilus influenzae, 
H. parainfluenzae, H. aphrophilus, H. paraphrophilus, Cardio-
bacterium hominis, Eikenella corrodens and Kingella kingae. 
They are all small Gram-negative bacteria, frequent colo-
nizers of the oral cavity, slow growing and capnophilic 
although these bacteria are not phylogenetically related. 
Guntheroth in 1984 and Roberts in 1999 described that 
dental infection, dental treatments, or general dental hygiene 
procedures may be the portal of entry for these bacteria.7,8
All HACEK microorganisms cause 3% of all cases of in-
fective endocarditis (IE) and among them, A. actinomyce-
temcomitans is the most frequently involved.9 This species 
is easily isolated, although it requires a prolonged incubation 
time. Blood cultures were positive in 90% of cases of A. ac-
tinomycetemcomitans infection when incubated for longer 
than 8 days.9 According to a review by Paturel et al, these mi-
crobes were found in only 55.5% of patients who received 
echocardiography.10 Previous studies have uncovered several 
characteristics of IE caused by A. actinomycetemcomitans 
including intermittent fever, weight loss, peripheral signs 
of endocarditis, anemia and microscopic hematuria.6,9,10 
Besides IE, the pathogen may cause soft tissue abscess, 
periodontitis, chest wall destruction and infection of 
other rare sites.11–13 This report describes 11 cases of inva-
sive A. actinomycetemcomitans infection which were treated 
at National Taiwan University Hospital from January 
1985 to December 2004.
Methods
Bacterial isolates and antimicrobial susceptibility testing
All the isolates of A. actinomycetemcomitans were Gram-
negative coccobacilli with positive catalase reactions. 
These isolates were identified at a species level by both 
conventional biochemical methods and using the Neisseria-
Haemophilus Identification (NHI) card (Vitek, Biomérieux, 
Las Halles, France). Antimicrobial susceptibility of these 
isolates for penicillin, ampicillin, amoxicillin-clavulanate, 
ampicillin-sulbactam, ceftriaxone and clindamycin were 
determined by the disk diffusion method using Hueller–
Hinton agar supplemented with 5% sheep blood, at 5% CO2 
for 2 days in accordance with the guidelines recommended 
by the Clinical and Laboratory Standards Institute.14,15
Patients
Invasive infection due to A. actinomycetemcomitans was de-
fined as isolation of the organism from a normally sterile 
body site. A total of 11 patients with invasive A. actinomyc-
etemcomitans infections were identified from January 1985 
to December 2004. These patients were treated at National 
on the patients with probable infective endocarditis but growth was demonstrated in only four of these 
patients. Blood culture yielded A. actinomycetemcomitans after prolonged incubation. Three isolates were 
resistant to penicillin and two of these were also resistant to ampicillin.
CONCLUSION: The diagnosis of invasive A. actinomycetemcomitans infection was delayed due to the indo-
lent clinical course, non-specific presentation and slow growth of the organism. Antibiotic therapy using 
amoxicillin/clavulanic acid, ampicillin, ampicillin/sulbactam, ceftriaxone, clindamycin, cefotaxime, or 
levofloxacin was successful in all patients. None of the patients demonstrated recurrence of infection 
2–36 months following treatment.
KEYWORDS: Aggregatibacter (Actinobacillus) actinomycetemcomitans, invasive infection, Taiwan
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Taiwan University Hospital, a university-affiliated hospital 
with a 2,000 bed capacity located in northern Taiwan. 
Data on demographic characteristics, underlying disease, 
recent hospitalization in the 3 months prior to presentation, 
clinical manifestations of the patients, antimicrobial ther-
apy and outcome were retrospectively analyzed.
Definitions
All included patients fulfilled the modified Duke criteria 
for definite or possible IE, as proposed by Li et al.16 Renal 
dysfunction was defined as a serum creatinine level greater 
than 1.5 mg/dL (133 mM), and liver dysfunction as eleva-
tion of liver enzymes by more than twice the upper limit 
of normal (aspartate aminotransferase > 74 U/L, alanine 
aminotransferase > 82 U/L). Neurological complications 
included cerebral emboli or ischemic stroke, mycotic an-
eurysm with or without cerebral hemorrhage, and cerebral 
abscess. Renal complications included acute renal failure, 
defined as an increase of serum creatinine by more than 
0.5 mg/dL (44 mM) upon admission, or glomerulonephritis. 
Embolic complications included splenic infarct or ab-
scess, coronary embolism with myocardial infarction, pul-
monary embolism and peripheral limb embolization, but 
cerebral embolization was not included. Cardiac compli-
cations included new atrioventricular conduction block, 
intracardiac abscess and heart failure.
Results
Eleven patients with invasive infections due to A. actino-
mycetemcomitans, including five previously reported cases,13,17 
were identified in our hospital from 1985 to 2004 (Table). 
Eight of these patients had A. actinomycetemcomitans endo-
carditis. One patient had osteonecrosis and the other two 
patients presented with pneumonia and chest wall mass 
lesions.
Among the eight patients with A. actinomycetemcomitans 
endocarditis, there were five men and three women with 
a mean age of 46 years. Four had rheumatic heart disease 
(3 had prosthetic valve replacement and 1 had a ventricular 
septal defect post prosthetic valve replacement). The most 
common presenting symptoms were fever (8/8) and cough 
(6/8), and the duration of symptoms before diagnosis var-
ied from 2 weeks to 9 months. Hematuria was noted in 
five patients and anemia in seven patients. Only one patient 
had leukocytosis. Transthoracic echocardiography (TTE) 
and/or transesophageal echocardiography (TEE) were per-
formed on the patients with probable IE but bacteria were 
demonstrated in only four of these patients (3 in mitral 
valves and 1 in aortic valve). Two mitral valve lesions were 
detected by both TTE and TEE (Patients 8 and 9) and one 
mitral (Patient 2) and one aortic valve (Patient 10) lesion 
was demonstrated by TTE (TEE was not done in these 
2 patients). Blood culture was positive from the 7th day to 
the 6th week of incubation. Three isolates were resistant to 
penicillin and two of were resistant to ampicillin. All isolates 
were susceptible to amoxicillin-clavulanate, ampicillin-
sulbactam, ceftriaxone and clindamycin. Diagnosis was 
delayed due to the indolent clinical course, nonspecific 
presentation and the slow growth of the organism.
Both patients with pneumonia and chest wall mass 
lesions due to A. actinomycetemcomitans (Patients 6 and 11) 
had dental problems and one (Patient 6) had an atrial sep-
tal defect type II post patch repair 18 years ago. The TTE 
showed no bacterial growth in both cases. Patient 5 had 
A. actinomycetemcomitans infection in the left mandibular os-
teoradionecrosis (ORN) with skin fistula formation. She had 
a history of nasopharyngeal carcinoma post-radiotherapy 
in 1988. In December 2002, pain and swelling was found 
at the left periauricular area. Incision and drainage was 
done and the pus yielded A. actinomycetemcomitans. She 
received clindamycin for 1 week and hyperbaric oxygen 
therapy 40 times over 2 months. The lesions healed and 
no recurrence was noted until recently.
All patients responded to treatments and were cured 
after intravenous or oral antibiotic therapy, which in-
cluded amoxicillin/clavulanic acid (18.2%), ampicillin 
(9.1%), ampicillin/sulbactam (9.1%), gentamicin (18.2%), 
ceftriaxone (27.3%), clindamycin (9.1%), cefotaxime (9.1%) 
and levofloxacin (9.1%). All patients were free of evidence 
of recurrence throughout the follow up periods ranging 
from 2 to 24 months.
Discussion
Patients 6 and 11 had A. actinomycetemcomitans pneumonia 
and chest wall infection, which was similar to a previously 
reported case.12 Patient 6 had underlying cardiopathy and 
both Patients 6 and 11 had dental caries. Underlying car-
diopathy in patients with A. actinomycetemcomitans infection 
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was frequently found not only in patients with endocardi-
tis but also in patients with other infection foci. Only a 
few pathogens cause concomitant infection of the lung 
and the soft tissue of the chest wall over the pneumonic 
area, these include Actinomyces and Mycobacterium tuber-
culosis. The infection may present with a diffuse alveolar-
filling process, occasionally extending into the pleural 
space or chest wall. This disease pattern is easily misinter-
preted as malignancy initially. In this study, we also re-
ported a patient with left mandibular ORN (Patient 5) 
with skin fistula formation. The infection was treated 
successfully with oral clindamycin and hyperbaric oxygen 
therapy. Although mixed flora was reported in mandibu-
lar ORN, A. actinomycetemcomitans was frequently found.18 
A. actinomycetemcomitans infection should be included as 
a differential etiology of mandibular ORN superimposed 
infection.
Paturel et al reviewed 102 cases of A. actinomycetemcomitans 
endocarditis and found that 73 patients were male and 
29 were female.10 Fourteen of the female patients (50%) con-
tracted the infection between the ages of 50 and 70 years, 
and 53% of men developed endocarditis between the ages 
of 40 and 60 years. The age range of our patients was 26–67 
years, similar to the patients reported by Paturel et al. Of 
the 102 cases, 27 had prosthetic valves. In their study, in-
termittent fever was observed in all patients, and weight 
loss and peripheral signs of endocarditis were also com-
mon. Anemia and microscopic hematuria were frequent 
findings and our patients also presented with symptoms 
of fever, coughing and hematuria. According to Paturel et al 
the disease was insidious, with mean symptom duration 
of 13 weeks before diagnosis, as confirmed by blood cultures 
incubated for greater than 5 days. In our results, the dura-
tion of symptoms before diagnosis varied from 2 weeks to 
9 months. Paturel et al also reported that the aortic valve 
was most commonly involved; however, in our study the 
mitral valve was more commonly involved. Complications 
occurred in 63% of patients from the study conducted by 
Paturel et al, with emboli being the most common, but no 
complications were evident in our patients.
The oral cavity is considered the most common portal 
of entry for A. actinomycetemcomitans infection. This mi-
croorganism is part of the normal oral flora and can be 
found in 25–30% of adults,19,20 and in 78% of the healthy 
Chinese population.21 A. actinomycetemcomitans is strongly 
associated with periodontopathy, especially juvenile peri-
odontitis, and can cause endocarditis, bacteremia and 
polymicrobial wound infections.9 In 1998, Storm et al22 
reported that dental treatment procedures were not a risk 
factor for IE. The bacteria may gain entry to the vascular 
system through dental procedures, dental infections, daily 
oral hygiene procedures or mastication.7,8 Among the 102 
patients reviewed by Paturel et al,10 43 had dental disease 
including carious teeth, periodontitis or retained roots. In 
our study, 81.8% (9/11) had an underlying dental disease. 
The finding of a high prevalence rate of dental disease 
may have been due to the awareness of its relationship to 
A. actinomycetemcomitans infection, endocarditis, pneumonia 
and ORN with superimposed infection. A high colonization 
rate of A. actinomycetemcomitans in Taiwan may contribute 
to these infections.23,24
The optimal antimicrobial therapy for invasive A. actin-
omycetemcomitans infection is not known. This organism 
usually has in vitro susceptibility to cephalosporin, amino-
glycosides, fluoroquinolones and tetracycline. Suscep-
tibility to ampicillin and penicillin G is variable. It is 
generally resistant to vancomycin, erythromycin and clin-
damycin.25–28 Though a fluoroquinolone showed supe-
rior effects against A. actinomycetemcomitans in a previous 
study,28 intravenous ampicillin or amoxicillin with gen-
tamicin should be the treatment of choice for A. actino-
mycetemcomitans infection.29 According to the American 
Heart Association, the duration of treatment should be 
4 weeks for native valve infection and 6 weeks for pros-
thetic valve endocarditis.29 Surgical treatment should be 
reserved for treatment failure, persistent infection, or 
complications. Amoxicillin can be expected to be effective 
as endocarditis prophylaxis in patients harboring A. actin-
omycetemcomitans who have underlying cardiopathy and 
undergo dental procedures.30 
Analysis of this case series suggests that underlying 
dental disease and cardiopathy are risk factors for A. actin-
omycetemcomitans endocarditis. The relationship between 
the harboring of A. actinomycetemcomitans in the oral cavity 
and the development of invasive A. actinomycetemcomitans 
infection remains unclear. Due to the low incidence of 
A. actinomycetemcomitans infection, it is not easy to evalu-
ate the efficacy of prophylactic antibiotics prior to dental 
treatment.31 The frequently insidious initial presentation 
of A. actinomycetemcomitans infection and delayed diagnosis 
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also complicates analysis of the need for prophylactic an-
tibiotics. The delay in diagnosis is exaggerated by the slow 
growth of this organism. Brouqui et al reported the mean 
duration of blood culture before detection of growth was 
7.1 days.29 Thus, a longer incubation time should be re-
quested for patients with prolonged constitutional symp-
toms, including fever, chills, malaise, anorexia and weight 
loss. Polymerase chain reaction amplification of universal 
bacterial loci and subsequent sequencing for identifica-
tion of possible causal microorganisms may be helpful.32 
The clinical presentation of A. actinomycetemcomitans is 
usually insidious and the fastidious growth of the organism 
almost always leads to delayed microbiological diagnosis. 
In patients with underlying cardiopathy, or dental disease 
with a subacute or chronic illness, A. actinomycetemcomitans 
endocarditis should be considered. Diagnosis is based on 
blood cultures but a prolonged incubation period should 
be requested. Ampicillin or amoxicillin with gentamicin 
combination could be the therapy of choice, but isolation 
of the organism and in vitro drug sensitivity testing is very 
important to appropriate management. Prolonged treat-
ment is required according to the clinical manifestations.
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